A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma November 16, 2017 Sponsor Tocagen Protocol Number Tocagen Tg 511-15-01 To Learn More Call (201)-510-0950
